***N*-(3-Chlorophenyl)-3-(pyridin-2-yl)-[1,2,4]triazolo[4,3-a]pyrazine-5-carboxamide, OSM-S-262**

****

Representative Example: http://malaria.ourexperiment.org/uri/6d1

Prepared according to General Procedure **F** from: **OSM-S-XXX** (100 mg, 0.28 mmol) to give the title compound as a beige powder (56 mg, 57%); **m.p.** 222–224 ˚C; **IR** νmax (film) /cm-1 3055, 2918, 1686, 1591, 1536, 1425, 1310; **1H NMR** (400 MHz, DMSO-d*6*) δ: 11.21 (1H, s), 9.73 (1H, s), 8.42 (1H, s), 8.29 (1H, ddd, *J* 4.9, 1.8, 1.0), 8.15 (1H, dt, *J* 7.8, 1.1), 8.02 (1H, td, *J* 7.7, 1.7), 7.58 (1H, t, *J* 2.3), 7.41 (1H, ddd, *J* 7.6, 4.8, 1.2), 7.38–7.36 (2H, m), 7.19 (1H, dtapp, *J* 6.8, 2.1); **13C NMR** (100 MHz, DMSO-d*6*) δ: 158.56, 148.30, 146.91, 146.53, 146.44, 146.05, 139.58, 137.83, 133.01, 130.97, 130.56, 124.89, 124.61, 124.05, 123.39, 119.16, 118.14; **m/z** (ESI+) 351 [M+H]+, 373 [M+Na]+; **HRMS** (APCI+) found 351.07547 [M+H]+, C17H12ClN6O requires 351.07556.

*O=C(C1=CN=CC2=NN=C(C3=NC=CC=C3)N21)NC4=CC=CC(Cl)=C4*

*InChI=1S/C17H11ClN6O/c18-11-4-3-5-12(8-11)21-17(25)14-9-19-10-15-22-23-16(24(14)15)13-6-1-2-7-20-13/h1-10H,(H,21,25)*